

GENVARA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2025 AND LYTHAM PARTNERS 2025 INVESTOR HEALTHCARE SUMMIT

Westminster, CO, January 8, 2025 – Genvara Biopharma, Inc., a biopharmaceutical company developing pharmacogenetically-targeted therapies for cardiovascular diseases acting through novel mechanisms of action, today announced that Thomas Keuer, Chief Executive Officer, will present at the Biotech Showcase 2025, taking place January 13-15, 2025 in San Francisco, California and Genvara will also participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.

Genvara's corporate presentation at the Biotech Showcase 2025 is scheduled for Monday, January 13, 2025 at 9:30 a.m. Pacific time. The Company's presentation is posted in the Science section of its website (<u>www.genvarabio.com</u>).

The Lytham Partners 2025 Investor Healthcare Summit Genvara presentation will take place at 1:00 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/. A replay of the webcast will also be available through same links.

About Genvara Biopharma

Genvara Biopharma's mission is to develop pharmacogenetically-targeted cardiovascular drugs acting through novel mechanisms of action. For more information, please visit www.genvarabiopharma.com.

Investor & Media Contact: Tom Keuer 720.940.2116

###